Transposagen Biopharmaceuticals was founded in 2003 to commercialize gene editing technologies focused on preclinical drug development applications. The platform technologies, piggyBac transposon and Cas-CLOVER targeted nuclease, are effective for many applications with over 750 peer-reviewed publications.
In 2014 Transposagen’s piggyBac was licensed by Janssen for CAR-T therapy development which sparked two company spin-outs: Hera BioLabs which is a CRO focused on preclinical models and services and a cell and gene therapy company, Poseida Therapeutics. In the years that followed piggyBac gained notice from the human biologics production industry with three consecutive papers published by Eli Lilly1,2,3. Meanwhile Cas-CLOVER was applied to develop Hera’s platform in vivo model, the SRG rat, a SCID rat on the Sprague-Dawley background harboring a double knockout for the Rag2 and Il2rgamma genes with applications in oncology, immuno-oncology and other areas of pharmacology/toxicology being developed.
In 2018, Transposagen sold its piggyBac technology to Lonza AG for human biologics production applications. Gene editing applications in the agriculture and industrial bioprocessing industry were sold to Demeetra AgBio and the platform gene editing technologies for preclinical drug discovery and early development applications, including products, services and licensing, are owned by Hera BioLabs where an experienced staff with expert knowledge in gene editing and animal services operate in a state-of-the-art facility to apply these advanced technologies to accelerate your drug discovery and development efforts.
Transposagen’s mission is to provide academic and drug discovery researchers with comprehensive gene editing products and services, empowering their efforts to discover the next generation of therapeutics. We accomplish this mission through internal innovation, in-licensing of cutting-edge technologies, and building lasting relationships with strategic partners.
Transposagen's customers and partners include many of the top pharmaceutical and biotechnology companies in the world, as well as numerous academic laboratories and government agencies. Our team of experts understands the needs of biomedical researchers, working one-on-one with customers to provide the best models and reagents to fit their exact requirements.
Learn how our proprietary piggyBac™ transposase technology and Footprint-Free™ gene editing systems are advancing research in a variety of scientific applications.Learn More
Meet the people who make Transposagen a leader in genetically modified animal models, cell engineering services, and gene editing tools.Learn More